Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer.
Li H, Yu B, Li J, Su L, Yan M, Zhu Z, Liu B. · 2014
Read Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. by Li H, Yu B, Li J, Su L, Yan M, Zhu Z, Liu B. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4039165.txt.
Introduction
Hao Li and six colleagues show that the long noncoding RNA H19 drives stomach cancer spread, in Oncotarget in 2014. H19 was already known to sit at higher levels in gastric cancer tissue than in matched healthy tissue. What it does there was unclear.
The team lowered H19 in one cancer cell line and raised it in another. Extra H19 made cells divide, move, invade, and seed new tumours more strongly. Cutting it back reversed those traits. A network search found two routes. H19 binds a protein partner whose levels rise with H19. H19 also carries a small RNA that suppresses a second gene. The work casts H19 as an active driver of this cancer, not a passive marker.
Catalog record
| CREATOR | Li H, Yu B, Li J, Su L, Yan M, Zhu Z, Liu B. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer By Hao Li, Beiqin Yu, Jianfang Li, Liping Su, Min Yan, Zhenggang Zhu, Bingya Liu Published in: Oncotarget DOI: 10.18632/oncotarget.1913 ABSTRACT Abstract Long non-coding RNAs (lncRNAs) play key roles in the progression and metastasis of some carcinomas. We previously showed that the expression of lncRNA H19 (H19) was higher in gastric cancer (GC) tissues than that in paired noncanerous tissues. However, the underlying mechanisms remain unclear. In this study, H19/miR-675 knockdown models in the MKN45 cell line and ectopic expression models in the SGC7901 cell line were established, and a co-expression network of H19 was generated to identify target genes by RIP and DLR. The results showed that overexpression of H19 promoted the features of GC including proliferation, migration, invasion and metastasis. An H19 co-expression network identified ISM1 as a binding protein of H19, and its expression was positively correlated with that of H19. CALN1 was identified as a target gene of miR-675 and its expression was negatively correlated with that of miR-675. H19 and MiR-675 function in a similar manner. However, H19 RNA actively binds to ISM1 and miR-675 targets CALN1. These differences suggest that H19 plays other roles besides encoding miR-675 in GC. Our results suggest that the effect of H19 in GC is mediated by the direct upregulation of ISM1 and the indirect suppression of CALN1 expression via miR-675. Keywords: gastric cancer, long non-coding RNA, H19, microRNA, miR-675 INTRODUCTION Gastric cancer (GC) is one of the most common cancers worldwide and its incidence is particularly high in East Asia and China. Approximately 988000 new cases of stomach cancer were reported in 2008 and the mortality rates in Eastern Asia were estimated at approximately 28.1 per 100,000 in men and 13.0 per 100,000 in women [1]. In China, the majority of GC patients are diagnosed at a late stage and their prognosis is poor. Therefore, elucidating the molecular mechanisms underlying GC progression is essential to identify key biomarkers and develop effective targeted therapies. The human genome project suggested that only 1.2% of the mammalian genome encodes proteins [2-3], and most of the genome is transcribed to tens of thousands of long (>200 nt) non-coding RNAs (ncRNA) [4-5]. An increasing number of non-coding RNAs have been found to play critical roles in cancer development and metastasis [6-8]. For example, lncRNA HOTAIR in the HOX locus can increase the invasiveness and metastatic potential of human breast cancer by inducing genome-wide re-targeting of Polycomb Repressive Complex 2 (PRC2) to an occupancy pattern, which leads to histone H3 lysine 27 trimethylation and changes in gene expression [9]. MALAT-1, an abundant lncRNA in many human cell types, was suggested to regulate the alternative splicing of a subset of pre-mRNAs by modulating serine/arginine splicing factor activity, which regulates tissue or cell-type–specific alternative splicing in a phosphorylation dependent manner [10]. LncRNA H19 was discovered in 1991 by Bartolomei and shown to lack a common open reading frame in the RNA or an encoded protein. H19 is highly expressed in extraembryonic tissues, the embryo proper and most fetal tissues but its expression is dramatically reduced after birth [11-12]. Recent studies showed that H19 is overexpressed in several malignancies such as breast cancer [13-14], bladder cancer [15-16] and cervical carcinomas [17]. H19 expression is significantly correlated with tumor grade and is a marker of early recurrence in bladder cancer. Likewise, ectopic H19 expression enhances the tumorigenic potential of hepatocellular carcinoma cells in vivo [6], suggesting that H19 may have oncogenic properties in these types of cancers. MiR-675 is a 23-nt RNA derived from nucleotides 1014−1036 of human H19 RNA [18]. Studies have shown that H19 can encode miR-675 and encoding miR-675 might be one of the important roles of H19 in human placental trophoblast cells and colorectal cancer cells [18-20]. However, whether H19 has any functions besides encoding miR-675 remains unknown. Whether the biological functions and co-expression network of H19 and miR-675 are the same is also unknown. In the present study, we examined the expressions of H19 and miR-675 in GC and their relationship with clinicopathological factors. Furthermore, the roles of H19 and miR-675 in the proliferation, migration, invasion and metastasis were investigated in vitro and in vivo to gain a better understanding of their relationship and function in GC. RESULTS H19 is up-regulated in gastric cancer and correlated with poor prognosis The Agilent G3 Human GE Microarray (8×60K) was used to analyze lncRNA expression profiles in 32 GC tissues and paired noncancerous mucosae. The first screening identified 48 candidate lncRNAs that differed significantly between cancer and paired noncancerous tissues based on three limitations (Fig.1A) as follows: 1) Absolute fold change of lncRNA between cancer and paired noncancerous tissues higher than two; 2) Length of lncRNA shorter than 3 kb; 3) Inclusion of the lncRNA in the lncRNA database. In the second screening, we analyzed the expression of the 48 lncRNAs in GC cell lines and tissues by quantitative PCR and finally focused on H19 in our study. [Figure: H19 and miR-675 are systematically up-regulated in gastric cancer and H19 has prognostic value for survivalA) Heat map representing unsupervised hierarchical clustering of 48 lncRNAs expression values of a panel of 32 gastric cancers relative to paired noncancerous tissues. Each column represents the paired tissue samples. Each row indicates 48 candidate lncRNAs based on the 3 limitations at the 1st screening. H19 is one such transcript (absolute fold change=6.6, P=0.0000361). B) Relative expression of H19 in 74 paired gastric cancer tumor tissues and noncancerous normal tissues. Statistical difference was analyzed by Wilcoxon signed–rank test (P=0.017). The relative expression of miR-675 showed the same pattern (data not shown). The H19 expression level was measured by quantitative reverse transcription-PCR. C) Kaplan-Meier curves for overall survival of the 74 patients with gastric cancer by H19 expression in tumor tissues (P=0.036). D) Positive correlation of H19 and miR-675 expression in 74 gastric cancer tissues.] Analysis of 74 paired clinical GC and noncancerous tissues showed a significant upregulation (mean: 6-fold) of the expression of H19 in cancer tissues compared with matched noncancerous tissues (Fig.1B). The 74 patients were then divided into two groups based on the fold-change of H19 expression as follows: H19-high (≥6-fold upregulation, n=36) and H19-low (<6-fold upregulation, n=38). In the univariate analysis, number of lymph nodes, metastasis, advanced TNM staging and H19 expression were significant prognostic factors (Table 1). However, no correlation between patient prognosis and age, gender, local invasion and Borrmann classification was observed. Pearson's correlation analysis showed that H19 expression was correlated with the number of lymph nodes and the clinical stage in our 74 patient samples (Tab.2). Kaplan-Meier survival analysis showed that patients with H19-high had a poorer prognosis than those with H19-low (P=0.036) (Fig.1C). These results suggested that a high H19 level is a significant predictor of death in GC. [Table: Evaluate the prognostic factors by univariate analyses] [Table: Pearson Correlation analysis] We also found that miR-675 expression was upregulated in tumor tissues compared to the paired noncancerous tissues. Furthermore, a positive correlation between H19 and miR-675 expression was observed in GC tissues (r=0.558, P=0.002) (Fig.1D) and cell lines, confirming that miR-675 is derived from H19. H19/miR-675 upregulation promotes cell proliferation in vitro Analysis